Review
Materials Science, Biomaterials
Xi Yang, Yuanfeng Wei, Lingnan Zheng, Jia You, Huawei Li, Ling Gao, Changyang Gong, Cheng Yi
Summary: This review provides an overview of PEI-based adjuvants and discusses strategies for improving and boosting immune response to vaccines, with a particular focus on their application in cancer vaccines. The potential challenges and future issues of PEI-based adjuvants in eliciting the effectiveness of cancer vaccines are also addressed.
JOURNAL OF MATERIALS CHEMISTRY B
(2022)
Article
Immunology
Xinpei Li, Shengqiu Liu, Panchao Yin, Kun Chen
Summary: Virus-mimetic polymeric nanostructures are a promising platform for enhanced immune responses and disease prevention. Using polymers as templates, various biomimetic structures can be designed and loaded with suitable antigens and metal oxide clusters to mimic the size and surface antigenicity of viruses. These structures can promote potent immune responses to protect humans from pathogens.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Immunology
Victor Araujo Correa, Amanda Izeli Portilho, Elizabeth De Gaspari
Summary: Vaccines are crucial in controlling infectious diseases, but most vaccines are not effective in providing mucosal protection. More research is needed to develop vaccines that can elicit mucosal immunity and provide protection at the first site of contact with pathogens.
Review
Immunology
Ting Huang, Li Liu, Zheng Lv, Kelei Zhao, Qiong Yi, Jing Zhang
Summary: Lung cancer is a major cause of patient deaths globally, and despite advancements in tumor immunotherapy, the 5-year survival rate for lung cancer patients remains low. The development of effective vaccines for lung cancer is crucial, and DNA vaccines are considered a promising strategy to activate the immune system against lung cancer due to their ability to induce both humoral and cellular immune responses.
Review
Biochemistry & Molecular Biology
Haneen Imad Abufares, Leen Oyoun Alsoud, Mohammad A. Y. Alqudah, Mohd Shara, Nelson C. Soares, Karem H. Alzoubi, Waseem El-Huneidi, Yasser Bustanji, Sameh S. M. Soliman, Mohammad H. Semreen
Summary: The COVID-19 pandemic has caused global crises, and the development of vaccines has become a collaborative effort worldwide. WHO-approved vaccines have been shown to be safe and effective, enhancing immune response and reducing the risk of infection. However, the type of vaccine and individual health status have significant impacts on immune responses.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Pharmacology & Pharmacy
Dalinda Eusebio, Ana R. Neves, Diana Costa, Swati Biswas, Gilberto Alves, Zhengrong Cui, Angela Sousa
Summary: DNA vaccines are innovative approaches that show great potential in overcoming the limitations of traditional vaccines. While plasmid DNA vaccines have numerous advantages, there are still challenges in improving their immunogenicity.
DRUG DISCOVERY TODAY
(2021)
Review
Biochemistry & Molecular Biology
Sneha Ratnapriya, Eva Perez-Greene, Luca Schifanella, Alon Herschhorn
Summary: Protection from HIV acquisition may require an effective vaccine that elicits antibodies against HIV-1 envelope glycoproteins, with adjuvants playing a crucial role in enhancing immune responses. Various adjuvants have been used in combination with HIV-1 envelope glycoproteins in recent years, showing potential to improve antibody responses and guide specific antibody formation.
Review
Immunology
Pooja Choudhary, Donaldson Magloire, Glenn Hamonic, Heather L. Wilson
Summary: The immune system in the upper reproductive tract provides protection against pathogens and immune tolerance against sperm and fetus. The timing of exposure to pathogens is most likely during estrus and breeding when the cervix is semi-permissive. The goal of intrauterine immunization is to induce local or systemic immunity and/or promote passive protection for suckling offspring.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Xiaoli Yu, Li Wang, Xinru Yang, Songsong Zhang, Guiwei Li, Lanlan Zhang, Jiaxuan Li, Xiaona Wang, Han Zhou, Yanping Jiang, Wen Cui, Yijing Li, Lijie Tang, Xinyuan Qiao
Summary: In this study, we developed Lactobacillus casei bacterial ghosts (BGs) for delivering DNA vaccines and demonstrated their ability to enhance immune responses. Our results showed that BGs could be efficiently taken up by macrophages and upregulated the expression of various immune-related genes. Additionally, BGs promoted the maturation and activation of dendritic cells (DCs), as well as increased T cell proliferation and specific antibody production. These findings suggest that L.casei BGs can serve as an effective delivery system for DNA vaccines.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Agriculture, Dairy & Animal Science
Adelijiang Wusiman, Yi Zhang, Telieke Ayihengbieke, Xike Cheng, Tuerhong Kudereti, Dandan Liu, Deyun Wang, Saifuding Abula
Summary: In this study, immunopotentiator Alhagi honey polysaccharide encapsulated PLGA nanoparticles (AHPP) and assembled pickering emulsion with AHPP as shell and squalene as core (PPAS) were prepared and their characteristics were investigated. The results showed that PPAS possessed good adjuvant activity and could induce strong and long-lasting cellular and humoral immune responses.
Article
Immunology
Emil Joseph Vergara, Andy Cano Tran, Mi-Young Kim, Tufaria Mussa, Matthew J. Paul, Thomas Harrison, Rajko Reljic
Summary: Tuberculosis is a major global health threat with a quarter of the global population harboring latent TB. A study found that intranasal administration of spore and nanoparticle-based subunit vaccines can enhance and alter lung and systemic immune responses. Additionally, individuals with latent TB in the TB-endemic country of Mozambique showed stronger CD4 T cell reactivity to the vaccine candidate.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Diego A. Diaz-Dinamarca, Michelle L. Salazar, Byron N. Castillo, Augusto Manubens, Abel E. Vasquez, Fabian Salazar, Maria Ines Becker
Summary: This review article discusses the potential role of protein-based adjuvants in vaccine development. Despite their structural differences, all protein-based adjuvants have significant immunostimulatory properties and interact with innate immune receptors, enhancing the effectiveness of vaccines. Therefore, protein-based adjuvants are expected to play an important role in the development of vaccines against different types of pathogens.
Review
Chemistry, Physical
Aihua Qu, Maozhong Sun, Liguang Xu, Liqiang Liu, Lingling Guo, Panpan Chen, Qing Wang, Zhiyong Du, Zhimeng Wu, Chuanlai Xu, Hua Kuang
Summary: Chiral nanomaterials play a crucial role in the field of vaccines by promoting antigen presentation and activating the immune system for tumor immunotherapy. However, there are still challenges in this research, such as finding better synthesis methods and addressing the issue of immune system regulation.
Article
Immunology
Anna Morena D'Alise, Linda Nocchi, Irene Garzia, Laura Secli, Luigia Infante, Fulvia Troise, Gabriella Cotugno, Simona Allocca, Giuseppina Romano, Armin Lahm, Guido Leoni, Emanuele Sasso, Elisa Scarselli, Alfredo Nicosia
Summary: Virus vectored genetic vaccines (Vvgv) are a promising approach for immune protection against infectious diseases and cancer. However, combining adjuvants with genetic vaccines has been challenging. In this study, the researchers developed a novel approach using an adenovirus vector to synchronize the activity of the genetic adjuvant with the vaccine. The results showed that this approach enhanced immune responses to viral and tumor antigens, suggesting its potential for more effective genetic vaccines.
FRONTIERS IN IMMUNOLOGY
(2023)
Letter
Medicine, General & Internal
Ai-ris Y. Collier, Jingyou Yu, Katherine McMahan, Jinyan Liu, Abishek Chandrashekar, Jenny S. Maron, Caroline Atyeo, David R. Martinez, Jessica L. Ansel, Ricardo Aguayo, Marjorie Rowe, Catherine Jacob-Dolan, Daniel Sellers, Julia Barrett, Kunza Ahmad, Tochi Anioke, Haley VanWyk, Sarah Gardner, Olivia Powers, Esther A. Bondzie, Huahua Wan, Ralph S. Baric, Galit Alter, Michele R. Hacker, Dan H. Barouch
Summary: The kinetics of immune response to Covid-19 vaccines were studied, showing varying peak levels and durations of response for different vaccines. However, the response levels correlating with protection have not been defined yet.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Medicine, General & Internal
Pablo Tebas, Christine C. Roberts, Kar Muthumani, Emma L. Reuschel, Sagar B. Kudchodkar, Faraz Zaidi, Scott White, Amir S. Khan, Trina Racine, Hyeree Choi, Jean Boyer, Young K. Park, Sylvie Trottier, Celine Remigio, Diane Krieger, Susan E. Spruill, Mark Bagarazzi, Gary P. Kobinger, David B. Weiner, Joel N. Maslow
Summary: The study presented encouraging data on a DNA vaccine against Zika virus infection in a phase 1 clinical trial. The vaccine elicited anti-ZIKV immune responses with no serious adverse events reported at the interim analysis. Further studies are needed to evaluate the safety and efficacy of the vaccine.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Ebony N. Gary, Bryce M. Warner, Elizabeth M. Parzych, Bryan D. Griffin, Xizhou Zhu, Nikesh Tailor, Nicholas J. Tursi, Mable Chan, Mansi Purwar, Robert Vendramelli, Jihae Choi, Kathy L. Frost, Sophia Reeder, Kevin Liaw, Edgar Tello, Ali R. Ali, Kun Yun, Yanlong Pei, Sylvia P. Thomas, Amira D. Rghei, Matthew M. Guilleman, Kar Muthumani, Trevor Smith, Sarah K. Wootton, Ami Patel, David B. Weiner, Darwyn Kobasa
Summary: A mouse model for SARS-CoV-2 infection based on AAV6.2FF-hACE2 transduction of the respiratory tract was developed and validated, showing promising results in vaccine testing. This genetically diverse mouse model represents a valuable tool for preclinical evaluation of interventions against SARS-CoV-2.
Review
Pharmacology & Pharmacy
Matthew R. Bell, Michele A. Kutzler
Summary: As people age, their immune system becomes less able to protect against infections and develop immunity from vaccination. With a growing elderly population and increased risk of pandemics, strategies to enhance vaccine responses in the elderly need to be developed and improved.
ADVANCED DRUG DELIVERY REVIEWS
(2022)
Article
Biotechnology & Applied Microbiology
Arun Sankaradoss, Suraj Jagtap, Junaid Nazir, Shefta E. Moula, Ayan Modak, Joshuah Fialho, Meenakshi Iyer, Jayanthi S. Shastri, Mary Dias, Ravisekhar Gadepalli, Alisha Aggarwal, Manoj Vedpathak, Sachee Agrawal, Awadhesh Pandit, Amul Nisheetha, Anuj Kumar, Mahasweta Bordoloi, Mohamed Shafi, Bhagyashree Shelar, Swathi S. Balachandra, Tina Damodar, Moses Muia Masika, Patrick Mwaura, Omu Anzala, Kar Muthumani, Ramanathan Sowdhamini, Guruprasad R. Medigeshi, Rahul Roy, Chitra Pattabiraman, Sudhir Krishna, Easwaran Sreekumar
Summary: The study developed a DNA vaccine candidate for dengue virus by combining different serotypes of envelope protein and non-structural protein 1. The vaccine induced neutralizing antibodies and antigen-specific T cell responses in mice, and passive transfer of immune sera provided protection. This alternative strategy for dengue vaccine design shows potential for broad-spectrum protection.
Retraction
Multidisciplinary Sciences
Kumar Sachin Singh, Rishabh Sharma, Poli Adi Narayana Reddy, Prashanthi Vonteddu, Madeline Good, Anjana Sundarrajan, Hyeree Choi, Kar Muthumani, Andrew Kossenkov, Aaron R. Goldman, Hsin-Yao Tang, Maxim Totrov, Joel Cassel, Maureen E. Murphy, Rajasekharan Somasundaram, Meenhard Herlyn, Joseph M. Salvino, Farokh Dotiwala
Article
Microbiology
Opeyemi S. Adeniji, Leticia Kuri-Cervantes, Chenfei Yu, Ziyang Xu, Michelle Ho, Glen M. Chew, Cecilia Shikuma, Costin Tomescu, Ashley F. George, Nadia R. Roan, Lishomwa C. Ndhlovu, Qin Liu, Kar Muthumani, David B. Weiner, Michael R. Betts, Han Xiao, Mohamed Abdel-Mohsen
Summary: Siglec-9 is an inhibitory receptor on NK cells that restrains cytotoxicity by binding to sialoglycans on target cells. Despite its inhibitory role, NK cells expressing Siglec-9 exhibit high cytotoxicity against HIV-infected cells. By disrupting Siglec/sialoglycan interactions, NK cells' capacity to kill infected cells can be enhanced. This study identifies a potentially important glyco-immune checkpoint mechanism that allows HIV-infected cells to evade immune surveillance.
Article
Microbiology
Abdullah M. Izmirly, Adam-Nicolas Pelletier, Jennifer Connors, Bhavani Taramangalam, Sawsan O. Alturki, Emma A. Gordon, Sana O. Alturki, Joshua C. Mell, Gokul Swaminathan, Vivin Karthik, Michele A. Kutzler, Esper G. Kallas, Rafick-Pierre Sekaly, Elias K. Haddad
Summary: It has been estimated that over 390 million people are infected by Dengue virus annually, resulting in about 96 million cases of clinical pathologies. The current licensed Dengue virus vaccine, CYD-TDV, is only recommended for seropositive individuals. This study investigates the influence of Dengue virus serostatus and immunological mechanisms on vaccine responses. The findings suggest that seropositive individuals exhibit a stronger immune response to the vaccine and have increased levels of T follicular helper cells and the chemokine CXCL13/BLC. This immune profile correlates with the ability to produce neutralizing antibodies against all four serotypes of Dengue virus. This study provides valuable insights for the development of Dengue vaccines and highlights the importance of studying serostatus in vaccine design.
Article
Medicine, Research & Experimental
Laura K. Aisenberg, Kimberly E. Rousseau, Katherine Cascino, Guido Massaccesi, William H. Aisenberg, Wensheng Luo, Kar Muthumani, David B. Weiner, Stephen S. Whitehead, Michael A. Chattergoon, Anna P. Durbin, Andrea L. Cox
Summary: Researchers have discovered that preexisting dengue virus antibodies can enhance interferon production in cells during secondary infection, providing protection against severe outcomes. This finding provides new insights into the role of antibodies in dengue and Zika virus infections.
Article
Geriatrics & Gerontology
Jennifer Connors, Bhavani Taramangalam, Gina Cusimano, Matthew R. Bell, Stephanie M. Matt, Kaitlyn Runner, Peter J. Gaskill, Victor DeFilippis, Janko Nikolich-Zugich, Michele A. Kutzler, Elias K. Haddad
Summary: Progressive impairment of immunity in older adults is a significant public health problem. This study demonstrates decreased expression of antiviral pathway proteins pIRF7 and pTBK-1 in older individuals, which correlates with impaired immune function.
Article
Microbiology
Pratima Saini, Opeyemi S. S. Adeniji, Devivasha Bordoloi, Jennifer Kinslow, Jeff Martinson, Danielle M. M. Parent, Kai Ying Hong, Jane Koshy, Abhijeet J. J. Kulkarni, Netanel F. F. Zilberstein, Robert A. A. Balk, James N. N. Moy, Leila B. B. Giron, Russell P. P. Tracy, Ali Keshavarzian, Kar Muthumani, Alan Landay, David B. B. Weiner, Mohamed Abdel-Mohsen
Summary: One mechanism that cancer cells use to evade NK cell immune surveillance is by expressing high levels of sialoglycans, which bind to the glyco-immune checkpoint molecule Siglec-9 on NK cells. SARS-CoV-2 infection alters the immunological profiles of NK cells. NK cells from hospitalized COVID-19 patients show impaired cytotoxicity against SARS-CoV-2 antigen-expressing cells, and this impairment is associated with higher plasma levels of SARS-CoV-2 nucleocapsid antigen. NK cells expressing Siglec-9 have higher cytotoxicity and blocking Siglec-9 enhances NK cell cytotoxicity against SARS-CoV-2-infected cells.
Article
Infectious Diseases
Woo Joo Kim, Christine C. Roberts, Joon Young Song, Jin Gu Yoon, Hye Seong, Hak-Jun Hyun, Hyojin Lee, Areum Gil, Yeeun Oh, Ji-eun Park, Bohyun Jeon, Ji-Eun Lee, Sang Kyu Choi, Sun Kyung Yoon, Sunhee Lee, Byoungguk Kim, Deborah Kane, Susan Spruill, Sagar B. Kudchodkar, Kar Muthumani, Young K. Park, Ijoo Kwon, Moonsup Jeong, Joel N. Maslow
Summary: The CoV2-001 phase I trial evaluated the safety and immunogenicity of the GLS5310 vaccine over 48 weeks. GLS-5310 was well tolerated and induced high levels of binding antibodies and T-cell responses. The vaccine demonstrated dose-independent antibody and T-cell responses.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Immunology
Joel N. Maslow, Ijoo Kwon, Sagar B. Kudchodkar, Deborah Kane, Amha Tadesse, Hyojin Lee, Young K. Park, Kar Muthumani, Christine C. Roberts
Summary: We discuss the advancements made in developing DNA vaccines during the SARS-CoV-2 pandemic. The article provides a comprehensive review of DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines offer advantages in terms of production speed, thermostability, safety profile, and cellular immune responses. Comparing three devices used in SARS-CoV-2 clinical trials, the GeneDerm suction device stands out with numerous benefits, especially for international vaccination campaigns. As a result, DNA vaccines hold promise for future pandemics.
Review
Biotechnology & Applied Microbiology
Jennifer Connors, Gina Cusimano, Nathan Mege, Kyra Woloszczuk, Emily Konopka, Matthew Bell, David Joyner, Jennifer Marcy, Virginie Tardif, Michele A. Kutzler, Roshell Muir, Elias K. Haddad
Summary: In the field of immunology, a systems biology approach is crucial for understanding the complex interplay between genetic, epigenetic, and environmental factors in the immune response to infection and vaccination. The innate immune response, which includes cell players and critical signaling pathways, is not a linear pathway but formed from complex networks and interactions. Systems-level analyses and expanded experimental technologies are needed to further understand the intricacies of the immune response.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2023)
Review
Immunology
Christopher Chung, Sagar B. Kudchodkar, Curtis N. Chung, Young K. Park, Ziyang Xu, Norbert Pardi, Mohamed Abdel-Mohsen, Kar Muthumani
Summary: Harnessing the immune system to combat disease has transformed medical treatment. Monoclonal antibodies have emerged as important immunotherapeutic agents with clinical relevance in treating a wide range of diseases. However, their production and administration are costly, time-consuming, and have limitations. Researchers are exploring new methods to increase the accessibility and utility of monoclonal antibody treatments.
Article
Oncology
Cindy Lin, Laura Garcia-Gerique, Erin E. Bonner, Jerome Mastio, Matthew Rosenwasser, Zachary Cruz, Michael Lawler, Luca Bernabei, Kar Muthumani, Qin Liu, Mortimer Poncz, Thomas Vogl, Marie Toerngren, Helena Eriksson, Dan T. Vogl, Dmitry I. Gabrilovich, Yulia Nefedova
Summary: Multiple myeloma is characterized by clonal proliferation of plasma cells in the bone marrow, and the tumor microenvironment plays a crucial role in disease progression. This study identifies S100A8/S100A9 proteins produced by neutrophils and monocytes as key regulators of megakaryocyte expansion, promoting multiple myeloma progression. Targeting S100A9 with tasquinimod has potent antimyeloma effects and may serve as a potential therapeutic strategy.
CANCER RESEARCH COMMUNICATIONS
(2023)
